This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Claudine Sapède
Director, Global HTA Policy at Novartis International


Claudine Sapède is Director, Global HTA Policy at Novartis in Global Public Affairs based in Basel, Switzerland. In this role, she focuses on value assessment, HTA and reimbursement decision-making approaches as well as their impact on patient access to innovative treatments. She engages with internal and external stakeholders involved in setting or shaping HTA, pricing and reimbursement decisions.

Claudine is currently a member and active contributor of the EFPIA’s market access and HTA working groups and co-lead one of the workstream related to the implementation of the EU HTA regulation.

Prior to this role, she has had a range of different roles in the field of pricing and market access both at country and global levels in consulting as well as large multinational pharma organizations. Her business career in the pharmaceutical sector over 20 years spans the full spectrum of evidence generation, value demonstration, market access strategies, pricing, and policy.

Agenda Sessions

  • HTA procedures in the European Union are being harmonized – the industry’s view.